Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
1201 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
1202 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 34
1203 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 63
1204 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Poland 72
1205 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Switzerland 69
1206 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 52
1207 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 26
1208 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 50
1209 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Poland 71
1210 Apheresis Allogeneic Anaplastic Large Cell Lymphoma Hematology 2025 Standard Therapy Germany 3
1211 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 71
1212 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 29
1213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 38
1214 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 28
1215 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 46
1216 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Spain 28
1217 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Slovakia 52
1218 Apheresis Allogeneic T-NHL Angioimmunoblastic T-cell Lymphoma Hematology 2025 Standard Therapy Germany 56
1219 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1220 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 23
1221 Apheresis Allogeneic Mielodysplastic syndrome Hematology 2025 Standard Therapy Spain 69
1222 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Brazil 71
1223 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 36
1224 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 58
1225 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Germany 68
1226 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 61
1227 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 35
1228 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 39
1229 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Serbia 58
1230 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 47
1231 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Netherlands 62
1232 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 69
1233 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy United Kingdom 35
1234 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 71
1235 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 70
1236 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1237 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 71
1238 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 39
1239 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1240 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 56
1241 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 65
1242 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Germany 65
1243 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
1244 Apheresis Autologous Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 32
1245 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 67
1246 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 56
1247 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Columbia 62
1248 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 46
1249 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 66
1250 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 46
1251 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 33
1252 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 31
1253 Apheresis Allogeneic B-Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 62
1254 Apheresis Allogeneic B-Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 62
1255 Apheresis Allogeneic Hemophagocytic lymphohistiocytosis Hematology 2025 Standard Therapy Czechia 27
1256 Apheresis Allogeneic Shwachman-Diamond Syndrome Hematology 2025 Standard Therapy Spain 11
1257 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 67
1258 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 60
1259 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy CROATIA 43
1260 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 69
1261 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Austria 61
1262 Apheresis Allogeneic Other Immune System Hematology 2025 Standard Therapy USA 62
1263 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
1264 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 63
1265 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1266 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Denmark 50
1267 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
1268 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Australia 71
1269 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 76
1270 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 66
1271 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 74
1272 Apheresis Allogeneic Morbus Hodgkin Hematology 2025 Standard Therapy Germany 21
1273 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy France 66
1274 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
1275 Apheresis Allogeneic T Lymphoblastic Lymphoma Hematology 2025 Standard Therapy Portugal 25
1276 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Romania 29
1277 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 37
1278 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 49
1279 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
1280 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1281 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 43
1282 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Serbia 32
1283 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 66
1284 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1286 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 68
1287 Apheresis Allogeneic OMDS/ Myeloproliferative Neoplasie Hematology 2025 Standard Therapy Switzerland 46
1288 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 3
1289 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 75
1290 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 58
1291 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Greece 63
1292 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1293 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
1294 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Spain 49
1295 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 30
1296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
1297 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Canada 55
1298 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1299 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 16
1300 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 73